AlzeCure Pharma (ALZCUR) Q1 2025 earnings summary

Executive summary

• AlzeCure develops innovative small-molecule drugs for CNS diseases, focusing on Alzheimer's and pain, with three platforms: NeuroRestore, Alzstatin, and Painless.

• Q1 2025 saw significant progress, including a €2.5M EIC grant for a Phase II trial of NeuroRestore ACD856 and new preclinical data for both NeuroRestore and Alzstatin.

• The company presented at major conferences and published findings supporting the disease-modifying and anti-inflammatory effects of its lead candidates.

Financial highlights

• Net sales were SEK 0 thousand (0) for Q1 2025, consistent with prior periods.

• Operating loss for Q1 2025 was SEK -10,238 thousand (-9,998), and net loss was SEK -10,108 thousand (-9,804) compared to Q1 2024.

• Earnings per share, basic, was SEK -0.11 (-0.16) for Q1 2025.

• Cash and cash equivalents at period end were SEK 20,819 thousand (19,037).

• Research expenses accounted for 65.2% (70.1%) of operating expenses in Q1 2025.

Outlook and guidance

• The EIC grant will accelerate clinical development of ACD856, with potential for additional EIC fund investment.

• The company is exploring further financing options and potential licensing or partnership deals to strengthen its cash position.

• AlzeCure aims to advance its diversified portfolio, targeting high unmet needs in Alzheimer's and pain, and maximize shareholder value through out-licensing and partnerships.